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Abstract
Background: Probiotics are live microorganisms that, when administered in adequate amounts, should confer a
health benefit to the host. Media sources tend to present probiotics as an appealing health promotion method
able to prevent or treat a wide variety of clinical conditions. In obstetrics and gynaecology, Lactobacilli species are
mainly used to restore the physiologic vaginal microbiota in order to treat bacterial vaginosis and vulvovaginal
candidiasis (VVC) and prevent preterm birth.
Discussion: Several RCTs investigated the potential benefits of probiotics in gynaecological and obstetrics conditions.
For all potential indications, recent specific meta-analyses have been published. Considering vulvovaginal candidiasis in
non-pregnant women, probiotics slightly improved the short-term clinical and mycological cure, and reduced the
1-month relapse. However, no important impact of probiotic use was observed on long-term clinical or mycological
cure. Similarly, the addition of probiotics to metronidazole for the treatment of bacterial vaginosis was not shown to
provide any additional benefit. In obstetrics, using probiotics during pregnancy neither decreased nor increased the risk
of preterm birth before 34 weeks or before 37 weeks. Similarly, no benefits emerged for gestational diabetes, preterm
premature rupture of membrane, and small and large for gestational age infants.
Conclusion: Despite increasing marketing of probiotics for the treatment of vulvovaginal candidiasis and prevention of
preterm birth robust evidence demonstrating a beneficial effect is scarce. Moreover, there was considerable heterogeneity
among the different studies in terms of route of administration, strain/s of probiotic adopted, and length of probiotic use.
Before recommending the systematic use of probiotics to treat bacterial vaginosis and VVC and prevent preterm birth,
high-quality research is needed. Professional medical associations should issue recommendations defining if, when, and
how probiotics should be used for gynaecological disorders.
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Background
According to the World Health Organization (WHO),
probiotics are live microorganisms that, when adminis-
tered in adequate amounts, confer a health benefit to
the host [1]. Probiotics can be ingested with diet or in
supplement forms [2]. Their consumption has been
proven effective for the management of some gastro-
intestinal conditions, such as irritable bowel syndrome,
and for the prevention of diarrhoea associated with
Clostridium difficile infection [3, 4].
In the last decade, many clinical trials have been con-
ducted to assess the effects of probiotics in the preven-
tion and treatment of a broad range of disorders, and
the scientific interest in this field is growing. Searching
Medline through PubMed for “probiotics”, identifies
14.188 articles published between 2007 and 2017
(accessed 14 January 2018), with an increase of 163%
from 2007 to 2017 in the number of articles published
per year. In the obstetrical and gynaecological field
probiotics, administered both orally and vaginally, have
been mainly tested for the prevention and treatment of
vaginal infections and for the prevention of preterm
birth [2, 5–8]. The rationale of using oral probiotics in
the treatment of gynaecological conditions is related to
the ability of these microorganisms to survive through
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the gastrointestinal system and to ascend to the vaginal
tract after their excretion from the rectum; whereas
vaginal administration allows a direct and targeted
colonization action of the probiotics for restoring
unhealthy vaginal microbiota [9].
Also, the use of probiotics is progressively expanding.
In particular, women of reproductive age are prone to
use these products for gastrointestinal symptoms [10].
Another important catchment area is represented by
pregnant women, as it is estimated that up to 1 woman
out of 7 in the Netherlands regularly use probiotics dur-
ing gestation [11].
Media sources tend to present probiotics as an appeal-
ing health promotion method able to prevent or treat a
wide variety of clinical conditions [12]. Indeed, in 2015
probiotics market exceeded $35 billion and it is esti-
mated to continue to rise in the years to come [13]. An
estimate based on a survey conducted for FederSalus
(the main Italian referent for institutional and commer-
cial organizations operating in the field of food supple-
ments) on more than 6000 individuals representing the
Italian population aged 18 and above, indicated that 32
million Italians have used a nutritional supplement in
the last year [14]. In Italy, from November 2016 to Octo-
ber 2017 the market of nutritional supplements reached
2.9 € billions, for a total of almost 212 million packs
sold, with an increase in turnover of 7.3% [15]. In par-
ticular, in Italy the probiotic market reached € 343 mil-
lion in 2016, ranking first among the best-selling food
supplements [16]. In other Western countries the sce-
nario is similar. In fact, in the North American market
(United States and Canada) probiotic represent the cat-
egory of nutritional supplement with the higher growth
in absolute terms (+$725 million) in the period 2009–
2014 [17].
Given this background, the time has come to verify
whether probiotics really benefits pregnant and
non-pregnant women, and whether the magnitude of
the effect justifies the expenditure.
Probiotics in non-pregnant women
Vaginal infections represent one of the most common
reason for gynaecological consultation [7]. It is estimated
that approximately seven women out of 10 will experi-
ence at least one episode of vulvovaginal candidiasis
(VVC) in their lives [18]. Bacterial vaginosis (BV) is an-
other highly prevalent vaginal disorder associated with
an increased risk for pelvic inflammatory disease, sexu-
ally transmitted infections, HIV transmission, and pre-
term delivery [19]. Bacterial vaginosis is characterized by
a reduction or depletion of lactobacilli and overgrowth
of Gardnerella vaginalis, Mycoplasma hominis, Prevo-
tella species, and other pathogenic anaerobic bacteria
[18]. Lactobacillus species produce lactic and acetic acid
and hydrogen peroxide, maintain the vaginal pH around
4.5 or less, hamper growth of pathogenic bacteria and
Candida albicans, and are thus considered protective
against VVC and BV [19, 20]. Accordingly, the putative
beneficial effect of Lactobacillus species-containing pro-
biotics in restoring and maintaining the physiologic vagi-
nal microbiota, fostered their use for the treatment of
both vaginal disorders.
The effectiveness of probiotics for the treatment of
VVC in non-pregnant women was recently evaluated in
a Cochrane systematic review [7]. A total of 10 RCTs
(1656 participants) investigating the effect of probiotics
used by the oral and vaginal route as a complementary
therapy to conventional antifungal drugs were included.
Probiotics slightly improved the short-term clinical and
mycological cure rate (risk ratio (RR) 1.14, 95% CI 1.05–
1.24, and RR 1.06, 95% CI 1.02–1.10 respectively), and
reduced the 1-month relapse rate (RR 0.34, 95% CI
0.17–0.68). However, no important impact of probiotic
use was observed on long-term clinical or mycological
cure rate (3-month post-treatment evaluation, RR 1.30,
95% CI 1.00–1.70; and RR 1.16, 95% CI 1.00–1.35, re-
spectively). Given the low- or very low-quality of the
considered studies, the authors emphasized the need for
further and better designed RCTs with larger sample
size, standardized methodology for probiotic prepar-
ation, and longer follow-up, in order to define also other
outcomes that may matter to women, such as time to
first relapse, need for repeated or prolonged treatments,
patient satisfaction, and cost effectiveness. However, we
have to underline that one of the major and unresolved
issues related to the treatment of VVC is the high rate
of recurrences even after the use of conventional azoles
treatment [21, 22]. In addition, treatment of recurrent
VVC, defined as four or more symptomatic episodes
within 12months, could be challenging due to the in-
creased presence of azole-drug resistance [23]. More-
over, in complicated forms, all treatments, including
antimycotics, are not supportive of long-term beneficial
results. In this particular sub-group of patients, the pro-
tective role of specific Lactobacillus species-containing
probiotics, such as Lactobacillus plantarum P17630, has
been proven effective as a potential empirical preventive
agent of VVC recurrences [23].
The putative beneficial effect of probiotics supplemen-
tation for the treatment of BV has been assessed in vari-
ous meta-analysis [8, 24, 25]. A 2009 Cochrane review
[24] showed promising results derived from the use of
oral and vaginal probiotics combined with metronidazole
or used alone. In 2013, a systematic review [25] sup-
ported the potential beneficial effect of probiotics for the
treatment of BV. Huang et al. [25] included in their ana-
lysis twelve RCTs published between 1992 and 2012;
probiotics were adopted either orally (n = 8) or vaginally
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(n = 4), with follow-up periods ranging from 4 weeks to
6 months. The pooled result showed that probiotics sup-
plementation was able to significantly improve the cure
rate in adult BV patients (RR 1.53, 95% CI 1.19–1.97).
Subgroup analyses failed to demonstrate a beneficial ef-
fect of probiotics supplementation in terms of long-term
(> 1month) follow-up (RR 1.15, 95% CI 0.89–1.47), and
a substantial heterogeneity was shown across different
study designs. Finally, in a recent meta-analysis [8], the
authors compared the use of metronidazole alone with
the combination of this antibiotic plus probiotics. Five
RCTs including a total of 1186 participants were
selected. An overall risk ratio of 0.98 (95% CI 0.91–1.06;
P = 0.57) was observed for the cure rate achieved with
combined therapy over metronidazole alone on BV.
At now, given the presence of inconclusive results,
some international guidelines do not support the use of
probiotics for the treatment of vulvovaginal infections
(Table 1).
Probiotics in pregnant women
It has been suggested that probiotics could play a role in
the prevention of preterm birth [2, 6]. Preterm birth
rates vary across different countries, ranging from 5 to
9% in Europe to 13% in USA [26]. The aetiology of
preterm birth is multifactorial, but it has been estimated
that about one third of cases is due to intrauterine in-
flammation [26] caused by ascending vaginal infections.
In particular, a pre-existing BV appears to be strongly
associated with premature birth [5].
Therefore, here the putative role of probiotics might
be associated with their potential ability to displace and
kill pathogens. The hypothesized mechanisms include
the development of anti-inflammatory cytokines and the
reduction of the vaginal pH, so that the vaginal environ-
ment becomes again favourable to the growth of healthy
bacteria [6, 20]. Moreover, the use of probiotics in
pregnancy could improve maternal glucidic metabolism
through the modification of gut microbial composition
and function, as well as the improvement of insulin
sensitivity [27].
To verify these hypotheses, Jarde et al. [2] performed a
systematic review and meta-analysis on the risk of preterm
birth and other adverse pregnancy outcomes in women
with a singleton pregnancy receiving probiotics. In this
analysis the authors included also prebiotics, i.e. food in-
gredients that indirectly induce the growth or activity of
beneficial microorganisms. A total of 21 studies (4098
women) were included in the final analysis. Five studies
(1017 women) evaluated the risk of preterm birth < 34
weeks of gestation, whereas the risk < 37 weeks was
assessed in 11 studies (2484 women). Using probiotics
during pregnancy neither decreased nor increased the risk
of preterm birth before 34 weeks (RR 1.03; 95% CI:0.29–
3.64) or before 37 weeks (RR 1.08; 95% CI: 0.71–1.63). In
addition, the authors did not observe a protective effect of
probiotics supplementation on most of the secondary out-
comes considered, including gestational diabetes, preterm
premature rupture of membrane (PPROM), and small and
large for gestational age infants. The only statistically sig-
nificant difference in favour of probiotics supplementation
regarded glucose metabolism (Homeostatic Model Assess-
ment of Insulin Resistance (HOMA-IR) and Insulin); how-
ever, the pooled estimate on gestational diabetes did not
Table 1 Role of probiotics in International guidelines for the treatment of vulvovaginal infections
Guideline Role of probiotics
European (IUSTI/WHO) guideline, 2011 [39] Potential role of vaginal probiotics in the management of recurrent BV
Faculty of Sexual & Reproductive Healthcare, Royal College of
Obstetricians and Gynaecologists (RCOG), 2012 [40]
Recurrent BV:
There is currently insufficient evidence to recommend the use of probiotics
either before, during or after antibiotic treatment as a means of reducing
recurrence.
Recurrent VVC:
Non-conventional management regimens such as dietary changes, use of
probiotics, tea tree oil and not wearing tight clothing have been studied.
There is currently insufficient evidence to support their recommendation in
treatment.
German Society for Gynecology and Obstetrics, 2015 [41] Probiotics have shown encouraging, but controversial results and require
further investigation
Society of Obstetrician and Gynaecologyst of Canada (SOGC),
2015 [42]
Current evidence of the efficacy of alternative therapies for bacterial vaginosis
(probiotics, vitamin C) is limited (I).
Centers for Disease Control and Prevention (CDC), 2015 [43] Overall, no studies support the addition of any available lactobacillus
formulations or probiotic as an adjunctive or replacement therapy in women
with BV. Further research efforts to determine the role of these regimens in
BV treatment and prevention are ongoing
IUSTI/WHO = International Union against Sexually Transmitted Infection and the World Health Organization
BV = bacterial vaginosis
VVC = vulvovaginal candidiasis
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show any benefit from probiotics intake (RR 1.25; 95% CI
0.61–2.56).
In contrast with these results, a Greek RCT [28]
showed a benefit of probiotic administration in women
with PPROM. Patients were allocated to 10-days vaginal
probiotic supplementation in combination with anti-
biotic prophylaxis (n = 59) or to standard antibiotic
treatment alone (n = 57). In women treated with the
double regimen significantly higher mean gestational age
at birth (35.49 vs 32.53 weeks) and latency period
(5.60 vs 2.48 weeks) were observed in comparison to
control group.
A recent Norwegian population based-prospective
cohort study [29] investigated the potential association
between the consumption of probiotic milk and the inci-
dence of preterm delivery and preeclampsia. Maternal
inflammatory response represents the common back-
ground of these two pathologic conditions, and the po-
tential anti-inflammatory effect of probiotics represents
the criterion for their use [30, 31]. The authors showed
that probiotic milk consumption during late pregnancy,
but not before or in early pregnancy, was associated with
a reduced risk of preeclampsia (adjusted OR: 0.80; 95%
CI, 0.64-0.94). Regarding preterm birth, ingestion of
probiotic milk during early pregnancy, but not before or
in late pregnancy, was associated with a reduction in risk
of preterm delivery (adjusted OR: 0.79; 95% CI,
0.64-0.97). In both cases, no dose-response relationship
was found.
The putative role of oral probiotics on vaginal
micro-environment in pregnancy has been evaluated by
Gille et al. [32] in a randomized, triple-blind, controlled
trial (RCT) conducted on 320 women. Participants were
allocated to oral probiotic supplementation or placebo.
The primary study outcome was the proportion of swabs
with normal Nugent score (< 4) after eight weeks of treat-
ment. Oral probiotics did not increase the proportion of
normal vaginal microbiota compared to placebo. At
post-intervention analysis, the proportion of normal vagi-
nal microbiota decreased from 82.6 to 77.8% in the pro-
biotic group, and from 79.1 to 74.3% in the placebo group,
without significant between-group difference (P = 0.29).
An Australian double-blind RCT [33] assessed the im-
pact of oral probiotics on vaginal Group B Streptococcal
(GBS) colonization rates in 34 women. Only women
with a GBS-positive vaginal swab at 36 weeks were
deemed eligible for the study. Patients were assigned to
daily oral probiotics plus standard antenatal care (inter-
vention group) or standard antenatal care (control
group) for three weeks or until delivery. At the end of
the treatment period, no significant between-group dif-
ference was observed in GBS infection rate.
Finally, the results of a recent systematic review [34]
do not support the treatment of BV-positive pregnant
women with probiotics with the objective of reducing
the risk of spontaneous preterm delivery.
Probiotics in obstetrics and gynaecology:
patient’s health or industry wealth?
From a commercial point of view, it appears that the
“golden era” of probiotics has begun. In the words of
Arnold [35] “like all good bacteria, probiotics have
sprung forth and multiplied. Trillions live in our guts,
and even more have begun to occupy grocery store
shelves”. However, to be defined a “probiotic”, the strain
of bacteria must have demonstrated health benefits [35].
The theoretical benefits deriving from the increase in
the number of healthy vaginal bacteria at the expenses
of potentially pathogenic micro-organisms appears intui-
tive. However, in many cases it is unclear whether the al-
teration of the vaginal microbiota is a consequence of
incidental infections or of a systemic endocrine/im-
munologic/metabolic condition predisposing to lactoba-
cillus extinction. In the former case, re-introducing
physiologic bacteria after pharmacological eradication of
pathogens seems rational, but in the latter one it would
result in trying to cure the consequence rather than the
origin of the disorder. The high BV and VVC relapse
rate observed after both antibiotic treatment and
complementary probiotic use suggests that the second
hypothesis might be true. If this is the case, probiotics
might reveal no more than an incomplete, temporary,
and expensive remedy. Another practical issue is the
route of administration. In fact, whether intravaginal
insertion of probiotics seems logical [19], aiming at
modifying the vaginal microbiota via oral ingestion of
physiologic bacteria appears less intuitive, and implies
ingested probiotics to reach the rectum, ascend the
vagina, and dislodge bacterial pathogens and yeasts [20].
Disappointingly, the widespread use of probiotics to
reduce the risk of preterm delivery and to improve the
cure rate of BV and VVC does not seem to be justified
by the currently available data. In fact, despite increasing
marketing and sales of probiotics, the results originated
by clinical trials are inconsistent and generally of
sub-optimal quality. Moreover, a substantial proportion
of these trials have been sponsored by parties with a
commercial interest in the outcome [36]. In addition,
there was considerable heterogeneity in published
studies in term of strain/s of probiotic adopted, route
of administration (oral, vaginal), and duration of
treatment [36].
The effects of probiotics seem to be strain-specific and
dose-dependent, and the lack of a standardized manu-
facturing process could affect microbial survival, growth,
and viability [37]. Along this line, a recent position paper
by The European Society for Paediatric Gastroenterology
Hepatology and Nutrition (ESPGHAN) Working Group
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provides evidence on the inadequate quality of commer-
cial probiotic products, in terms of definition of micro-
organisms, their numbers, functional properties, and
presence of contaminating microorganisms. The Work-
ing Group suggests the creation of certified laboratories
where the quality control of probiotics should be per-
formed using universally shared validated and standard-
ized methodologies [37]. In addition, as it is the case
with drugs, adverse events potentially related to the use
of probiotics, should be reported to and registered by
health authorities [37].
The regulatory aspects related with the production
and marketing of these products constitute another rea-
son of concern for both patients/consumers and physi-
cians. The regulation of probiotics differs between
countries without a universally shared framework [38].
In general, probiotic products are classified as food or
dietary supplements, and their development process has
to fulfil considerably less rigorous regulatory criteria
compared with drugs [37]. However, if probiotics are to
be prescribed to patients with specific disorders, they
should be regulated as drugs rather than foods or sup-
plements. Nevertheless, we are not aware of any indica-
tion to probiotic use in obstetrics and gynaecology
approved by national and supranational regulatory agen-
cies such as Food and Drug Administration (FDA) and
European Medical Agency (EMA).
Indeed, the somewhat vague manufacturers claims
may generate a sort of nobody’s land where commercial
interests may flourish independently of the effect of pro-
biotics for the prevention and treatment of specific dis-
orders [35]. In fact, as in most countries the regulation
of probiotics is focused on the legitimacy of any claim
rather than on their efficacy, manufacturers are careful
not to mention definite medical indications for their
products [38]. In this regard, professional medical asso-
ciations should issue recommendations concerning the
role of probiotics in obstetrics and gynaecology, as their
uncontrolled implementation might also lead to a poten-
tially harmful decrease in the use of effective standard
drug treatments.
The primary aim of probiotics is the re-establishment
of a physiological vaginal microbiome. However, there is
currently no consensus regarding their use for the treat-
ment of vaginal infections and their sequelae. Thus, fur-
ther better-quality data are needed to define the real
effect size of probiotic use in different obstetrical and
gynaecological conditions. At the very least, our duty is
to provide complete and quantitative information to
patients/consumers, allowing them to decide whether
probiotics are worth their cost.
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